AVLSA
KLRA

Atlas Venture Life Science Advisors’s Kailera Therapeutics KLRA Stock Holding History

Atlas Venture Life Science Advisors’s Portfolio KLRA Stock Details KLRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$114M Buy
+5,171,282
New +$114M 12.93% 4

Other funds holding KLRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Atlas Venture Life Science Advisors's KLRA Position: Q2 2026 in Review

Atlas Venture Life Science Advisors opened a new position in Kailera Therapeutics (KLRA) in Q2 2026: 5,171,282 shares worth $114M. The stake represents 12.93% of the portfolio and ranks #4 among its holdings.

47 funds tracked by Wall St. Rank hold KLRA as of Q2 2026.

  • Atlas Venture Life Science Advisors held 5,171,282 shares of Kailera Therapeutics worth $114M as of Q2 2026.
  • Kailera Therapeutics was a new Atlas Venture Life Science Advisors position in Q2 2026.
  • Kailera Therapeutics made up 12.93% of Atlas Venture Life Science Advisors's portfolio in Q2 2026, its #4 holding.
  • 47 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q2 2026.

Based on Atlas Venture Life Science Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.